Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Non-Current Liabilities (2022 - 2025)

BioXcel Therapeutics has reported Other Non-Current Liabilities over the past 4 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.8 million for Q4 2025, down 73.01% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 73.01% YoY), and the annual figure for FY2025 was $1.8 million, down 73.01%.
  • Other Non-Current Liabilities for Q4 2025 was $1.8 million at BioXcel Therapeutics, down from $3.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for BTAI hit a ceiling of $21.2 million in Q1 2024 and a floor of $1.8 million in Q4 2025.
  • Median Other Non-Current Liabilities over the past 4 years was $2.6 million (2023), compared with a mean of $4.5 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 724.48% in 2024 and later plummeted 84.57% in 2025.
  • BioXcel Therapeutics' Other Non-Current Liabilities stood at $2.3 million in 2022, then decreased by 18.69% to $1.9 million in 2023, then soared by 248.19% to $6.6 million in 2024, then tumbled by 73.01% to $1.8 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $1.8 million (Q4 2025), $3.6 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.